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doi:10.1Objective: We describe the long-term results of aortic arch replacement using a trifurcated graft, including an
assessment of survival, neurologic complications, and graft patency.
Methods: A retrospective review was conducted on data from 206 consecutive patients (125 male; median age,
67 years; range, 20–87 years) who had a trifurcated graft used for aortic arch replacement between September
1999 and September 2009. Seventy-four patients (35.9%) had chronic dissection, 68 patients (33.0%) had ath-
erosclerotic aneurysms, and 39 patients (18.9%) had degenerative disease. Ninety-one patients (44.2%) had un-
dergone previous cardiac surgery.
Results: An elephant trunk was placed in 190 patients (92.2%) and completed in 101 patients (53.1%), with an
interval of less than 365 days between stages in 94 of 101 patients. Hospital mortality was 6.8% (14/206). Ad-
verse outcome (death/stroke within the first year postoperatively) occurred in 27.7% of patients (57/206; 50
deaths/7 strokes). Among 152 1-year survivors, the annual rates of transient ischemic attack and stroke were
0.85% and 1.1%, respectively. At 6 years, 75% of patients were still alive, compared with 92% in a matched
New York State control population (P< .001). Follow-up computed tomography scans (189 studies in 176/
206 patients [85.4%]) revealed 100% patency of the trifurcated graft limbs at a mean of 2.3 years.
Conclusions: Aortic arch replacement using a trifurcated graft is highly durable, with excellent patency in the
branch grafts, and is associated with a low incidence of cerebral embolization. However, the long-term outcome
in these patients is compromised by extensive comorbidities. (J Thorac Cardiovasc Surg 2010;140:S71-6)Cerebral injury is a devastating complication of aortic arch
replacement, with an enormous impact on quality of life
and long-term survival. Mounting evidence suggests that
the best method for cerebral protection in aortic arch surgery
is selective cerebral perfusion (SCP) combined with deep or
moderate hypothermic circulatory arrest (HCA).1-3
Especially in procedures requiring circulatory arrest exceed-
ing 30 minutes, antegrade SCP has been shown to preserve
cerebral oxygenation and attenuate derangements in cerebral
metabolism.4-6 Various methods for delivering SCP have
been developed, yielding low mortality rates and neurologic
injury.7-11 Nevertheless, cerebral embolism and malperfusion
during SCP remain problematic, highlighting the importance
of designing a technique to minimize these complications.12
Spielvogel and coworkers13-15 have published several
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The Journal of Thoracic and Carreplace the aortic arch. The technique has proven simple,
permitting expeditious arch reconstruction, yet versatile,
easily accommodating different anatomic situations.13-15
Moreover, the TG technique reduces the potential for
cerebral injury. First, administration of SCP via the right
axillary artery shortens the duration of HCA. Second,
excluding diseased portions of the arch and minimizing
manipulation of the brachiocephalic vessels both reduce
the potential for cerebral embolization. Short-term studies
of the TG technique have yielded low neurologic complica-
tion and in-hospital mortality rates.16 The current study fo-
cuses on long-term outcome, highlighting neurologic
events and the durability of the procedure.
MATERIALS AND METHODS
Patient Data Abstraction
From September 1999 to September 2009, 206 consecutive patients
(125 male, 81 female) underwent aortic arch replacement using a TG and hy-
pothermic SCP via direct axillary artery cannulation.17 This retrospective anal-
ysis, using review of medical records and telephone follow-up, was approved
by an institutional review board and did not require individual patient consent.
All patients who underwent the TG operation at our institutions during
this 10-year interval were included. The focus is on their long-term out-
come, regardless of whether the TG procedure was intended as a stand-
alone procedure or part of a planned 2-stage approach.
The median patient age was 67 years (range, 20–87 years). The most fre-
quent underlying causes for operation were chronic dissection (74; 37.3%),
atherosclerosis (68; 32%), and degenerative disease (39; 19.3%); other
causes are detailed in Table 1. Ninety-one patients (44.2%) had undergone
previous cardiac surgery (Table 2).diovascular Surgery c Volume 140, Number 6S S71
TABLE 1. Causes
n (%)
Chronic dissection 74 (35.9%)
Atherosclerosis 68 (33.0%)
Degenerative 39 (18.9%)
Ruptured atherosclerotic ulcer 8 (3.9%)
Marfan syndrome (non-dissected) 5 (2.4%)
Acute dissection 5 (2.4%)
Trauma 2 (1.0%)
Inflammatory aneurysm 2 (1.0%)
Other 2 (1.0%)
False aneurysm 1 (0.5%)
TABLE 2. Spectrum of previous cardiothoracic procedures (n ¼ 91)
n (%)
Procedures for acute type A dissection
Ascending interposition graft 36 (39.5%)
Ascending and aortic root replacement 13 (14.3%)
Ascending and aortic arch replacement 3 (3.3%)
Other aortic procedures
Aortic root replacement 12 (13.2%)
Thoracoabdominal aneurysm repair 9 (9.9%)
Other cardiac procedures
Coronary artery bypass grafts 8 (8.8%)
Aortic valve replacement 5 (5.5%)
AVR and CABG 4 (4.4%)
Triple-valve replacement 1 (1.1%)
AVR, Aortic valve replacement; CABG, coronary artery bypass grafting.
Abbreviations and Acronyms
AO ¼ adverse outcome
CT ¼ computed tomography
ET ¼ elephant trunk
HCA ¼ hypothermic circulatory arrest
SCP ¼ selective cerebral perfusion
TG ¼ trifurcated graft
Aortic Symposium 2010 Bischoff et alRisk factors for adverse outcome (AO) included smoking (78 patients;
36 active smokers, 42 past smokers), chronic obstructive pulmonary disease
(28 patients; 13.6%), neurologic events (24 patients; 19 with stroke, 5 with
transient ischemic attack), coronary artery disease (16 patients; 7.8%),
insulin-dependent diabetes mellitus (10 patients; 4.9%), and dialysis-
dependent renal failure (10 patients; 4.9%).
The mean maximal diameter of the aorta was 6.0  1.3 cm (range, 4.0–
12.0 cm). The extent of aortic replacement varied depending on the under-
lying disease. Isolated arch replacement was undertaken in 49 patients
(23.8%). Concomitant procedures included ascending aortic replacement
(102; 49.5%), ascending and root replacement (26; 12.6%), descending
aortic replacement (8; 3.9%), and simultaneous coronary artery bypass
grafting (53; 25.7%).
An elephant trunk (ET) procedure was performed in 190 of 206 patients
(92.2%); in 69 patients (33.5%), no further procedure was undertaken. A
completion stage II ET was performed in 101 patients (53.2%), using an en-
dograft in 5 patients. The median interval between stages I and II was 65
days (range, 0–4.3 years; 2 simultaneously); the interval was 30 days or
less in 22 patients (21.8%), 30 to 100 days in 45 patients (44.6%), and
more than 100 days in 32 patients (31.7%).
Operative Technique
Details of the TG technique have been described.13-16 A custom TG can
be constructed or a commercially prepared graft can be used (MAQUET,
Wayne, NJ). Briefly, the arch is approached via a median sternotomy or
bilateral anterior thoracotomy. With the aorta crossclamped and perfusing
via direct axillary artery cannulation, the proximal aortic reconstruction is
performed while cooling toward 15C. HCA is initiated when jugular
bulb saturation is 95% or greater, indicating maximum cerebral metabolic
suppression. During circulatory arrest, the brachiocephalic vessels are
transected approximately 1 cm beyond their origins; the presence of
macroscopic atherosclerotic disease may warrant further resection. The
arch vessels are serially anastomosed with 5-0 polypropylene sutures. The
left subclavian artery typically is attached first, followed by the left
common carotid and innominate arteries. By clamping the main limb of
the TG, axillary perfusion is resumed, providing hypothermic SCP to the
head and upper extremities. The perfusate temperature is allowed to drift
upward during the remaining arch repair, and active rewarming is not
begun until full systemic flow is resumed. The ET anastomosis is
constructed proximal to the left subclavian artery origin. A graft-to-graft
anastomosis is constructed between the ET graft and the proximal repair,
and the TG can be anastomosed to the neo-ascending aorta without inter-
rupting cerebral circulation.
Follow-up
This retrospective review was conducted using contemporaneously gath-
ered data and follow-up involving direct telephone interviews of the patient,
a close relative, or the referring physician. A standardized questionnaire in-
cluded queries about general health, cerebral vascular accidents, rehospital-
ization, reoperation, complications, and medications. Three patients (1.5%)
were lost to follow-up after 63, 86, and 1099 days. Follow-up was 98.5%S72 The Journal of Thoracic and Cardiovascular Surgcomplete, and median follow-up time was 3.7 years (range, 63 days to
9.6 years).
Computed Tomography Scans
The latest contrast-enhanced computed tomography (CT) scans were
reviewed for each patient, focusing on graft patency, change of caliber at
the anastomotic site, and the presence of dissection.
Statistical Analysis
Risk factors for AO and long-term survival were estimated by Cox pro-
portional hazards regression. Survival curves were estimated using a Ka-
plan–Meier curve, and Poisson regression was used to estimate the
standardized mortality ratio, relative to the 2004 New York State mortality
rates matched by gender and age. Linearized rates for permanent and tem-
porary neurologic dysfunction were calculated by dividing the number of
events by the corresponding person-years of exposure. In all of these anal-
yses, follow-up was measured from the time of surgery, or from 1 year after
surgery, to the earlier date of death or of last contact alive, as appropriate.
For analyses regarding AO, follow-up was terminated at the earlier time
of stroke, death, last contact alive, or end of observation period.RESULTS
Analysis of Results
With the desire to focus on the true long-term outcome,
AO was defined as death or occurrence of permanent stroke
within 1 year of surgery. Neurologic impairment was cate-
gorized as stroke (whether hemorrhagic, ischemic, or ofery c December 2010
TABLE 3. Adverse outcome: Causes of death (n ¼ 50)
Cause of death n (%)
Aortic rupture 9 (18%)
Cardiac failure 7 (14%)
Bischoff et al Aortic Symposium 2010unknown nature) or transient neurologic dysfunction: post-
operative confusion, agitation, delirium, prolonged obtunda-
tion, or Parkinson-like symptoms, with no focal deficit on
CT or magnetic resonance imaging.Stroke 7 (14%, h ¼ 5; i ¼ 2)





h, Hemorrhagic stroke; i, ischemic stroke.Operative Technique
A TG was used in 194 of 206 cases. In 12 patients, a bifur-
cated graft was used because of a specific anatomic condi-
tion or previous operation (ie, carotid-to-subclavian
bypass). In total, these patients had 606 anastomoses, with
a mean of 2.9 anastomoses per patient.Postoperative Complications
Postoperative complications after aortic arch replacement
using a TG occurred in 66 patients (32%). The most fre-
quent complication was prolonged intubation (>48 hours)
in 27 patients (13.1%). Postoperative transient neurologic
dysfunction developed in 12 patients (5.8%). Bleeding
requiring return to the operating room was reported in 11
patients (5.3%). Nine patients (4.4%) required dialysis:
renal failure was permanent in 2 patients and transient in 7
patients. Cardiac complications occurred in 7 patients
(3.4%): 3 patients had episodes of atrial fibrillation, and 4
patients developed pericardial effusions. Permanent stroke
occurred in 7 patients (2 of them died, vide infra: hospital
mortality).
The median hospital stay was 11 days (range, 1–108
days). The median intensive care unit stay was 3 days (range,
1–108 days).Hospital Mortality
Overall hospital mortality (death in the hospital or within
30 days postoperatively) was 6.8% (14/206). Congestive
heart failure (n ¼ 3), stroke (n ¼ 2, ischemic ¼ 1,
hemorrhagic ¼ 1), aortic rupture (n ¼ 2), and bleeding
(n ¼ 2) were the most common causes of death. Respiratory
failure, myocardial infarction, gastric ulceration, uncontrol-
lable acidosis, and multiorgan failure each occurred in 1
patient.Adverse Outcome in the First Year
AO, defined as stroke or death within the first year post-
operatively, occurred in 27.7% of patients (57/206). There
were 50 deaths (including 7 fatal strokes) and 7 stroke survi-
vors (Table 3; Figure 1).
Nineteen patients had AO after planned stage II comple-
tion (completion group); AO also occurred in 15 patients
in whom stage II was planned but had not yet been per-
formed (intermediate group). In 11 patients with AO, no
stage II completion was considered (prophylactic group)
and in 5 patients no ET was placed (non-ET group). The re-
lationship between AO and the operative grouping described
is shown in Figure 1.The Journal of Thoracic and CarThe probability of 1-year survival without AO was 76%.
Risk factor analysis by multiple logistic regression analysis
of all 206 patients identified only age as a significant risk fac-
tor for AO (P ¼ .0015/hazard ratio ¼ 1.038).
Permanent Stroke
Within the first year after the TG operation, 14 strokes
were reported: 7 within the first 30 days and 7 between 30
days and 1 year postoperatively. Six strokes were ischemic,
6 strokes were hemorrhagic, and 2 strokes were of unknown
cause. The linearized rate of stroke between 30 days and
1 year was 4.8 per 100 patient-years (7 strokes/147.0
patient-years).
In the first 30 days after the operation, the ratio of ischemic/
hemorrhagic strokes was 2.5 (ischemic¼ 5, hemorrhagic¼ 2).
The median interval between operation and stroke was 2 days
(range, 0–12 days).
After 30 days, strokes were predominantly hemorrhagic,
with a ratio of 0.25 (ischemic ¼ 1, hemorrhagic ¼ 4, un-
known cause ¼ 2). Six of 7 patients with late stroke had un-
dergone reoperation after a median interval of 93 days
(range, 41–173 days) after the TG surgery and had their
event after the second operation.
Other Causes of Death
Between 30 days and 1 year after TG aortic arch repair,
aortic rupture occurred in 7 cases. Three patients had under-
gone ET stage II after an interval of 31, 76, and 164 days,
and had aortic rupture subsequently: 1 patient had a thora-
coabdominal aneurysm, and 1 patient had residual arch dis-
ease. Four patients died of cardiac failure; 2 of them had
undergone ET stage II completion 36 days and 173 days
after the TG operation. One patient died of bleeding 199
days after stage II repair, which was performed 144 days af-
ter the TG operation. In 8 patients, the cause of death re-
mains unknown: 5 patients (62.5%) had undergone
subsequent surgery for aortic aneurysm disease.
Long-Term Outcome and Survival
Reoperation at the arch vessels. Reoperation at the site of
the arch vessels was reported in 1 patient with bilateral sub-
clavian aneurysms caused by Marfan syndrome.diovascular Surgery c Volume 140, Number 6S S73
FIGURE 1. Flow chart of AO ([stroke]/death within first year) in relation to the first and second stage of aortic arch and descending/thoracoabdominal aortic
aneurysm repair with the ET technique. No ET was placed in the non-ET group; completion was not planned in the prophylactic group; the adverse events
occurred between the stages in the intermediate group; and the adverse events in the completion group occurred after stage II ET. ET, Elephant trunk.
FIGURE 2. Aortic arch replacement with a TG: Kaplan–Meier curve of
152 1-year survivors versus New York State population.
Aortic Symposium 2010 Bischoff et alLong-term survival. Calculations of long-term survival
are based on data from 152 patients who were alive 1 year
after the procedure. A total of 29 patients died during
follow-up after having survived the first year after the TG
procedure. Cause of death is unknown in 18 patients; among
those patients, 9 (50%) required subsequent surgery.
Multiple logistic regression analysis of the 152 1-year sur-
vivors identified only age as a significant risk factor for long-
term survival (P ¼ .018/hazard ratio ¼ 1.037).
Long-term survival was 94% and 78% 3 and 5 years
postoperatively, respectively. Comparison of the patient
population with an age- and gender-matched New York
State control group revealed a significantly lower survival
of the patients than of the control population (P< .001,
Figure 2). Calculated survival probabilities were .75 and
.92, respectively. Among the 152 1-year survivors, there
were 584 person-years of follow-up beyond the first year,
with 29 observed deaths and 14.6 expected deaths, yielding
an observed/expected ratio of 1.99 (P ¼ .0002, per Poisson
regression).
Long-term cerebral events. Among the 152 1-year survi-
vors, the linearized rate of stroke was calculated as 1.1 per
100 patient-years (6 strokes/707 patient-years). The strokes
occurred after a median interval of 2.7 years (range, 1.6–3.6
years). The nature of the stroke could not be determined in 4
cases; 2 were hemorrhagic. Three patients had undergone re-
operation and had strokes after the second operation. The
rate of transient ischemic attack was calculated as 0.85 per
100 patient-years (6 transient ischemic attacks in 721.8
patient-years).
A total of 98 of 124 contacted patients were taking antico-
agulants at the time of follow-up. Most patients were taking as-
pirin (51/98; 52.0%) or warfarin (Coumadin, Bristol-Myers
Squibb Co, Princeton, NJ [47/98; 48.0%]). Follow-up
revealed no episodes of bleeding or myocardial infarction.S74 The Journal of Thoracic and Cardiovascular SurgPatency of the trifurcated graft. To assess long-term du-
rability and arch graft patency, the latest available CT studies
were reviewed: 189 studies in 176 patients (85.4%). The
median interval between the operation and the CT angio-
gram was 1.6 years (range, 4 days to 7.9 years). All reviewed
scans showed widely patent TG limbs (Figure 3).
A CT angiogram was available in 122 of 127 surviving
patients (96.0%). The median interval between the TG oper-
ation and the last scan in which graft patency was demon-
strated was 2.8 years (range, 4 days to 8.0 years). The
median interval between the scan and the date of last
follow-up was 1.1 years (12 days to 9.7 years).
Of the patients who died, 55 of 79 (69.6%) had a review-
able CT scan. The median interval between the TG operation
and the latest scan showing graft patency was 76 days (range,
4 days to 4.4 years), whereas the median interval between the
last scan and the date of death was 186 days (range, 2 days toery c December 2010
FIGURE 3. Postoperative angiogram (A) and 3-dimensional reconstruction (B) of arch replacement with a trifurcated graft. Displayed are the left carotid
limb (1), left subclavian limb (2), and innominate limb (3).
Bischoff et al Aortic Symposium 20106.0 years). The median interval between the TG operation and
the date of death was 217 days (range, 17 days to 6.2 years).
DISCUSSION
Cerebral protection during aortic arch surgery is multifac-
eted. The basic technique of deep HCA has been used for
more than 20 years.18 However, episodes of deep HCA
exceeding 30 minutes have been shown to lead to memory
and fine motor deficits, resulting in temporary neurologic
dysfunction, with some evidence of subtle long-term
sequelae.19
Antegrade SCP extends the safe threshold of HCA20,21;
however, when administered directly into the arch vessels,
it carries a risk of dislodging atherosclerotic debris.
Several surgical techniques have been developed to
overcome this problem. Kazui and colleagues12 introduced
a 4-branched graft in which the brachiocephalic vessels are
implanted distal to their origins. This technique quickly
led to impressive results, with permanent and temporary
neurologic dysfunction rates of 4% in 50 consecutive pa-
tients with atherosclerotic arch aneurysms.
In 2002, Spielvogel and colleagues15 introduced the TG
technique, which not only uses SCP to minimize cerebral is-
chemia but also (in contrast with the Kazui technique)
avoids manipulation and direct cannulation of diseased or
atherosclerotic cephalic vessels because these vessels are
anastomosed during a brief interval of HC. In 2007, Spielvo-
gel22 presented 150 TG cases, with a stroke rate of 4.1% and
temporary neurologic deficit in 4.7%.
The current 30-day results are similar, with a rate of 3.4%
(7/206) for permanent neurologic injury and 5.8% (12/206)
for transient neurologic dysfunction. Although the TG tech-
nique yielded satisfactory early results, the need for further
procedures led to 21 adverse events during the first year after
surgery, including 15 deaths and 6 strokes (Figure 1). More
than 60% of this cohort underwent further surgery for aneu-
rysm repair after arch replacement. ET completion was the
most common reoperation: 69 of 101 ET stage II procedures
were carried out within 100 days of the TG operation. TheThe Journal of Thoracic and Carpresence of extensive aortic disease requiring staged proce-
dures is a major factor contributing to AO after the TG
procedure.
The study population has a high prevalence of comorbid-
ities and cardiovascular risk factors, including hypertension,
smoking, and older age. Notably, age was the only factor that
significantly influenced AO or long-term survival in our co-
hort (AO: P¼ .0015; long term survival: P¼ .018; Cox pro-
portional hazards regression). Age, however, is an important
factor because the aging process modifies other risk factors.23
Survival in our patients is significantly lower than in the
age- and gender-matched New York State control group
(P ¼ .0002, per Poisson regression). Although aortic rup-
ture, stroke, and heart disease played a significant part in
mortality in this high-risk cohort, we could not clearly iden-
tify the cause of death in 18 patients who died more than 1
year after the operation, which limits our analysis.
Among the 20 stroke victims, 10 had subsequent opera-
tions. In these cases, stroke occurred in only 1 patient after
the TG procedure; 9 of 10 patients had a stroke after a subse-
quent operation. The stroke pattern also changed over time,
from ischemic to hemorrhagic. The early ischemic strokes
were not unexpected, because postoperative stroke in aortic
arch operations usually results from cerebral emboli.24
Of 6 cases of stroke among the 152 1-year survivors, the
nature of the event remains unknown in 4, but 2 were caused
by intracranial bleeding. Eighty percent of strokes in the
general population are caused by emboli rather than hemor-
rhage,25 and 80% of our patients were taking Coumadin or
aspirin, including all 5 patients with stroke who could be in-
terviewed. It is therefore conceivable that the high preva-
lence of anticoagulation may have increased long-term
freedom from stroke in this patient collective, mitigating
their otherwise higher risk of cerebral embolization.
Review of the patients who died between 30 days and 1
year after TG surgery revealed that death resulting from car-
diac failure, aortic rupture, and bleeding (n¼ 12) occurred in
50% of patients after a more recent reoperation, usually ET
completion, which occurred at a median of 136 days after thediovascular Surgery c Volume 140, Number 6S S75
Aortic Symposium 2010 Bischoff et alTG procedure. It seems reasonable to attribute these deaths
to the consequences of extensive aortic disease rather than
to a failure of the TG operation, but the cause of death re-
mains unclear in 8 patients; thus, it is difficult to know
whether the TG operation played any significant role.
Examination of follow-up CT scans of the TG was an ap-
proach to determine the long-term durability and patency of
the graft. In lower-limb revascularization, long-term patency
is often less than 70%,26-28 whereas studies of splanchnic
and carotid subclavian bypass grafting show patency rates
of approximately 85%.29,30 Hughes and colleagues31 evalu-
ated TGs in hybrid aortic debranching, showing 100% graft
patency after a follow-up of 7.5 6.0 months and suggested
that high flow through these grafts contributes to their long-
term patency. Our review of available scans showed no graft
occlusion in any living patient after a median interval of 2.9
years, but we cannot rule out the possibility of graft failure in
some of the patients who died.CONCLUSIONS
The use of a TG for aortic arch replacement is character-
ized by a low incidence of cerebral injury, morbidity, and
mortality. Late strokes do not seem to be a direct conse-
quence of the TG operation. Our evaluation of graft patency
suggests that reimplantation of the cephalic vessels with
a TG can be performed with excellent long-term patency.
Although significant attrition occurs during the first postop-
erative year, it is a consequence of the underlying disease
and the need for subsequent treatment.References
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